- Name: Huang Pei-Yu
- Title: Chief Physician, Doctoral Supervisor
- Email: huangpy@sysucc.org.cn
- Phone:
Dr. Pei-yu Huang has rich clinical teaching experience and was honored as the excellent clinical instructor of Sun Yat-sen University in 2013.
Dr. Pei-yu Huang has conducted several clinical studies on nasopharyngeal cancer treatment, published in international authoritative journals such as The Lancet and JAMA-Oncology, and his results have been adopted by domestic and international authoritative guidelines such as NCCN guidelines in the United States and CSCO guidelines in China. He was awarded the first prize of Science and Technology Award of China Anti-Cancer Association in 2019 and 2023; and the first prize of Guangdong Medical Science and Technology Award in 2019.
2005.9 -2009.7 doctoral candidate of Sun Yat-sen University Cancer Center.
1.You R, Liu YP, Xie YL,...,Huang PY*, Chen MY*. Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023 Mar 18;401(10380):917-927. (IF 168.9 )
2.Chen SY, Duan XT, Li HF, Peng L, Wang ZQ, Xu GQ, Hua YJ, Zou X, You R, Ouyang YF, Liu YP, Gu CM, Yang Q, Jiang R, Zhang MX, Lin M, Xie YL, Lin C, Ding X, Xie RQ, Duan CY, Zhang WJ, Huang PY*, Chen MY*. Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial.Cell Rep Med 2023 Nov 21;4(11):101279. (IF 14.3 )
3.You R, Liu YP, Huang PY (co-first author), et al. Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial, JAMA Oncol. 2020 Sep 1;6(9):1345-1352. (IF 28.4 )
4. Huang PY, Zeng Q, Cao KJ, Guo X, Guo L, Mo HY, Wu PH, Qian CN, Mai HQ, Hong MH. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.Eur J Cancer. 2015 Sep;51(13):1760-70. (IF 8.4 )
5. Huang PY, Wang CT, Cao KJ, Guo X, Guo L, Mo HY, Wen BX, Wu YS, Mai HQ, Hong MH *. Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: Findings from a randomised trial. Eur J Cancer. 2013 May;49(8):1923-31. (IF 8.4 )
6. Peng PJ, Lv BJ, Wang ZH, Liao H, Liu YM, Lin Z, Con YY, Huang PY(Corresponding author). Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens.
Ther Adv Med Oncol. 2017 Feb;9（2）:68-74. (IF 4.9)
7. Wu,X, Huang PY (Co-first author), Peng, PJ，Han F, Zhao C, Zhang L*. Long term follow up of a PhaseIII Study Comparing Radiotherapy with or without Weekly Oxaliplatin for Locoregionally Advanced Nasopharyngeal Carcinoma. Ann Oncol. 2013 Aug;24(8):2131-6. (IF 50.5 )
8. Xue C, Huang Y, Huang PY (Co-first author), Yu QT, Pan JJ, Liu LZ, Song XQ, Lin SJ, Wu JX, Zhang JW, Zhao HY, Xu F, Liu JL, Hu ZH, Zhao LP, Zhao YY, Wu X, Zhang J, Ma YX, Zhang L*. Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol. 2013 Apr;24(4):1055-61. (IF 50.5 )
9. Zhang L, MacIsaac KD, Zhou T, Huang PY(Co-first author), Xin C, Dobson JR, Yu K, Chiang DY, Fan Y, Pelletier M, Wang Y, Jaeger S, Krishnamurthy Radhakrishnan V, JeBailey L, Skewes-Cox P, Zhang J, Fang W, Huang Y, Zhao H, Zhao Y, Li E, Peng B, Huang A, Dranoff G, Hammerman PS, Engelman J, Bitter H, Zeng YX, Yao Y. Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes. Mol Cancer Res. 2017 Dec;15（12）:1722-1732. (IF 5.2)
Updated by International Office, Sun Yat-sen University Cancer Center